June 13, 2018

FACIT Appoints Biotech Veteran Dr. David O’Neill as President

Entrepreneur adds US oncology management experience to Ontario commercialization

David o'NeillTORONTO, ON (June 13, 2018) — The Board of Trustees announced the appointment of David O’Neill as the President of FACIT. Dr O’Neill joined FACIT in 2013 as Vice President, Business Development, bringing cancer drug development expertise as well as an extensive business network in pharma and biotech. As Acting President for the last year, he has elevated the profile of the organization and enabled FACIT to continue to deliver critical commercialization financing to innovative start-ups in the growing Ontario market.

Continue reading – FACIT Appoints Biotech Veteran Dr. David O’Neill as President

May 1, 2018

Ontario Institute for Cancer Research welcomes new President and Scientific Director, Dr. Laszlo Radvanyi

Dr. Laszlo Radvanyi

Toronto (May 1, 2018) – Mr. Tom Closson, Chair of the Ontario Institute for Cancer Research’s (OICR) Board of Directors, today welcomed to the Institute Dr. Laszlo Radvanyi, OICR’s new President and Scientific Director. Radvanyi was selected after an extensive international search and has extensive oncology-related experience from his time spent in industry, with a particular focus in immuno-oncology. Radvanyi will work with the Ontario cancer research community, and OICR’s commercialization partner FACIT, to see that Ontario’s best innovations are reaching cancer patients as quickly as possible.

Radvanyi joins OICR from EMD Serono (Merck KGaA, Darmstadt Germany), where he was a Senior Vice President, Global Senior Scientific Advisor in Immunology and Immuno-Oncology. There he played a central scientific advisory role, facilitating major academic centre alliances and ran EMD Serono’s CAR T-cell program, in partnership with Intrexon. He also served as Global Head of the Immuno-Oncology Translational Innovation Platform, where he was instrumental in rebuilding immuno-oncology research at the company, hiring new world-class scientific staff, as well as pruning and re-orienting the discovery pipeline.

Continue reading – Ontario Institute for Cancer Research welcomes new President and Scientific Director, Dr. Laszlo Radvanyi

April 19, 2018

Landmark study links tumour evolution to prostate cancer severity

Largest-ever study of its kind uses a tumour’s past to accurately predict its future

Toronto (April 19, 2018) – Findings from Canadian Prostate Cancer Genome Network (CPC-GENE) researchers and their collaborators, published today in Cell, show that the aggressiveness of an individual prostate cancer can be accurately assessed by looking at how that tumour has evolved. This information can be used to determine what type and how much treatment should be given to each patient, or if any is needed at all.

The researchers analyzed the whole genome sequences of 293 localized prostate cancer tumours, linked to clinical outcome data. These were then further analyzed using machine learning, a type of statistical technique, to infer the evolutionary past of a tumour and to estimate its trajectory. They found that those tumours that had evolved to have multiple types of cancer cells, or subclones, were the most aggressive. Fifty-nine per cent of tumours in the study had this genetic diversity, with 61 per cent of those leading to relapse following standard therapy.

Continue reading – Landmark study links tumour evolution to prostate cancer severity

April 12, 2018

Restorative Breast Cancer Solution Start-Up Wins the 2018 FACIT Pitch Competition

Biotechnology competition modeled after popular TV program Dragons’ Den

TORONTO, ON (April 12, 2018) – A panel of investor-judges has selected Ontario-based oncology researcher Soror Sharifpoor of Polumiros Inc. as the winner of the 2018 FACIT Falcons’ Fortunes competition. The $50,000 award is intended to support further development of their innovative cancer research. FACIT runs the annual competition as part of its broader mandate to support translating research into Ontario companies to impact the lives of patients with cancer.

Now in its fifth year, the FACIT Falcons’ Fortunes competition is open to any Ontario-based oncology researcher (academics, research institutions, research hospitals and start-ups). Entrepreneurial scientists are invited to pitch innovative research ideas to a panel of four investors in a competition that is modeled after the popular CBC television program Dragons’ Den. The winners receive the $50,000 “Ernsting Entrepreneurship Award.” After follow-up technical evaluation of the underlying innovation, the money funds product development for one year.

Continue reading – Restorative Breast Cancer Solution Start-Up Wins the 2018 FACIT Pitch Competition

March 29, 2018

Canada’s largest health research platform teams up with University of Toronto to accelerate cancer and chronic disease research

The leaders of the CPTP stand in front of servers storing the Project's data.

Pictured (left to right): Dr. John Mc Laughlin, Executive Director of CPTP; Cindy Morton, Chief Executive Officer of the Canadian Partnership Against Cancer.; and Dr. Philip Awadalla, National Scientific Director of CPTP.

Canadian Partnership for Tomorrow Project (CPTP) enters a new era of scientific activity under the leadership of newly appointed National Scientific Director, Dr. Philip Awadalla

March 29, 2018 (Toronto) – The Canadian Partnership Against Cancer (“the Partnership”) today announced The University of Toronto’s Dalla Lana School of Public Health will be the new national scientific partner of the Canadian Partnership for Tomorrow Project (CPTP) – Canada’s national population cohort for precision health. This new scientific partner will enable a strong national scientific vision for CPTP and support leading-edge research on the possible causes of cancer and chronic diseases, leading to more made-in-Canada discoveries and breakthroughs. In addition, the University has announced that Ontario Institute for Cancer Research (OICR) will be its strategic partner to deliver the expertise and services needed to lead this key research platform.

Continue reading – Canada’s largest health research platform teams up with University of Toronto to accelerate cancer and chronic disease research

March 6, 2018

Canadian pancreatic cancer research team provides personalized medicine, new hope to patients

VANCOUVER – Canadian pancreatic cancer researchers are joining forces under a Terry Fox initiative bringing new hope for patients with this deadly disease.

“For many years it’s been hopeless from a patient perspective, and we are hoping to help shift this,” says Dr. Daniel Renouf (BC Cancer, University of British Columbia) who, along with Dr. David Schaeffer (UBC, Vancouver General Hospital), is leading a $5-million pan-Canadian, precision medicine initiative recently funded by the Terry Fox Research Institute.

A lack of early detection tests. Few known symptoms. Very limited treatment options. No known biomarkers that can be used to direct therapy.  These are among the clinical challenges team EPPIC, short for Enhanced Pancreatic Cancer Profiling for Individualized Care, is tackling over the next five years to improve personalized treatments for patients with pancreatic ductal adenocarcinoma (PDAC), a disease with just a nine per cent five-year survival rate.

“Our project focuses on metastatic cancer versus surgically resectable primary tumours, because this is the clinical problem we see most often,” says Dr. Schaeffer, noting a priority is to discern if the metastatic and primary tumour differ in their genetic make-up. Four out of five patients have metastatic cancer at the time of diagnosis and most will succumb within a year.

Patients are very keen to participate in the research study. “My push is to keep the support coming for the research, and to bring hope to other pancreatic cancer patients. This is a disease that needs more hope,” says Susan Stewart, 57, a North Vancouver resident who was diagnosed with Stage IV terminal pancreatic cancer in January 2017. She was enrolled immediately in EPPIC as well as a clinical trial where she received an experimental therapy. Although it is early days yet, her results today are promising.  Her pancreatic cancer tumour is no longer visible on CT scans, and the metastatic cancer on her liver has shrunk considerably. Her doctors are using the EPPIC results to try and understand why her tumour has had such an incredible response to the experimental treatment.

The EPPIC team aims to sequence metastatic pancreatic tumours of 400 patients in Quebec, Ontario, Alberta and British Columbia.  They hope to improve understanding of pancreatic cancer biology to individualize treatment strategies, and to facilitate the development of new treatment options.

This project is currently under way in Toronto and Vancouver, through two clinical trials (COMPASS and PanGen), and will be expanded shortly to include eligible patients in Kingston, Ottawa, Calgary, and Edmonton. The Montreal site opens this week. Genomic sequencing and bioinformatics analyses of patient tumours will be conducted at the Ontario Institute for Cancer Research (OICR) and the BC Cancer Genome Sciences Centre.

“This funding will allow us to bring leading-edge pancreatic cancer research to more Canadian patients and further advance our understanding how to best treat advanced pancreatic cancer,” says Dr. Steven Gallinger, Leader of OICR’s PanCuRx Translational Research Initiative, which supports the COMPASS trial. “Collaborating with the other research groups will more rapidly result in more robust findings that can help us accelerate the development of new treatment options.”

The team will also store and analyze the genomic and clinical data collected in a knowledge bank that will be shared by Canadian and international researchers seeking ways to improve treatment.  The bank will be the first of its kind in Canada.

Dr. Victor Ling, TFRI president and scientific director, is thrilled TFRI is funding this high-calibre precision medicine team to tackle such a hard-to-treat cancer. “Pancreatic cancer research has been historically underfunded, and we are very excited to be expanding such a successful personalized medicine project to patients across Canada.  We hope precision medicine may hold the key to finding better treatments for this incurable disease.”

EPPIC’s multidisciplinary team comprises clinicians and scientists from BC Cancer, Vancouver Coastal Health Research Institute, University of British Columbia, University of Calgary, University of Alberta, Princess Margaret Cancer Centre, University Health Network, OICR, McGill University Health Centre (MUHC) and the Research Institute of MUHC, Centre hospitalier de l’Université de Montréal, Queen’s University and the Ottawa Hospital.

In addition to Drs. Renouf and Schaeffer, other principal investigators of EPPIC and the COMPASS and PanGen trials are: Dr. Jennifer Knox and Steven Gallinger (Princess Margaret Cancer Centre/UHN/ OICR), Dr. George Zogopoulos (MUHC/Research Institute of MUHC/McGill University), and Dr. Oliver Bathe (Tom Baker Cancer Center, University of Calgary). Many of the team’s investigators are members of PancOne™, an initiative of Pancreatic Cancer Canada (PCC).

TFRI’s investment in EPPIC also builds on funding from BC Cancer Foundation, OICR, Princess Margaret Cancer Foundation, PCC and VGH and UBC Hospital Foundation. 

About The Terry Fox Research Institute (TFRI)

Launched in October 2007, The Terry Fox Research Institute is the brainchild of The Terry Fox Foundation and today functions as its research arm. TFRI seeks to improve significantly the outcomes of cancer research for the patient through a highly collaborative, team-oriented, milestone-based approach to research that will enable discoveries to translate quickly into practical solutions for cancer patients worldwide. TFRI collaborates with more than 80 cancer hospitals and research organizations across Canada. TFRI headquarters are in Vancouver, B.C. For more information please visit www.tfri.ca and follow us on Twitter (@tfri_research).

Media Contacts

Katelyn Verstraten, 604-675-8000 ext. 7630; 604-358-8898 (cell) kverstraten@tfri.ca

Kelly Curwin, 604-675-8223; 778-237-8158 (cell) kcurwin@tfri.ca

EPICC Backgrounder

March 6, 2018

Study shows that environmental exposures such as air pollution are more determinant of respiratory health than inherited genetics

Toronto (March 6, 2018) – Researchers have found strong evidence that environmental exposures, including air pollution, affect gene expressions associated with respiratory diseases much more than genetic ancestry. The study, published today in Nature Communications, analyzed more than 1.6 million data points from biological specimens, health questionnaires and environmental datasets, making this study one of the largest ever to examine the relationship between gene expression and environmental stimuli. These findings represent a groundbreaking use of big data to uncover the environmental factors that are behind diseases and inform strategies for prevention, an approach that would apply to a number of diseases, including cancer.

Genetic, health and disease data of participants from Montreal, Quebec City and Saguenay were linked with environmental information such as air pollution, walkability and access to food to see how these factors impact gene expression. Participants were enrolled in the Quebec arm (CARTaGENE) of the Canadian Partnership for Tomorrow Project (CPTP), which supports research into environmental, lifestyle and genetic factors related to the development and progression of cancer and chronic diseases. More than 300,000 Canadians, 1 per cent of the population, have enrolled in CPTP since its launch in 2008.

The study used deep characterization of gene expression signatures from participants and linked that data with environmental information. “We were surprised to find that we were able to stratify genetic ancestry within Quebec, identifying individuals whose descendants were from Montreal versus Saguenay for example,” explains Dr. Philip Awadalla, the study’s senior author. “This helped us to show how most gene expression is not derived by ancestry, and that environmental exposures associated with living in a particular city or region are more impactful on gene expression associated with disease traits than heritable variation.”

One of the main findings of the study was that exposure to higher levels of particulate matter and nitrous dioxide in the Saguenay area affected the expression of genes associated with oxygen pathways and respiratory function. This resulted in higher rates of respiratory ailments such as asthma and chronic obstructive pulmonary disease (COPD). The study also revealed that there are genetic variants that control how a person’s gene expression responds when exposed to environmental stimuli.

“This study demonstrates Ontario’s leadership in research and in particular, the importance of big data,” said Reza Moridi, Minister of Research, Innovation and Science. “Today, with quantities of data never before available, we are able to make important discoveries that will help us fight and overcome disease.”

“Our study shows how one can use the large scope and scale of data in Canada’s largest health cohort to better understand how our genes interact with environmental exposures and shape individual health,” says Awadalla. “I encourage all those engaged in this type of research, both in Canada and around the world, to take advantage of this resource.”

Awadalla is Director and Sr. Principal Investigator, Computational Biology, OICR, the Executive Scientific Director of the Ontario Health Study (Ontario’s CPTP cohort), Director of the Genome Canada, Canadian Data Integration Centre and Professor, Department of Molecular Genetics, Faculty of Medicine, University of Toronto.

Controlled access to cohort data and biological samples is available to researchers through the CPTP Data Portal and CARTaGENE.

About OICR

The Ontario Institute for Cancer Research (OICR) is a collaborative, not-for-profit research institute focused on accelerating the translation of new cancer research discoveries to patients around the world while maximizing the economic benefit of this research for the people of Ontario. Funding for OICR is provided by the Government of Ontario.

For more information, please contact:

Hal Costie
Senior Communications Officer
Ontario Institute for Cancer Research
647-963-5289
hal.costie@oicr.on.ca
@OICR_News

February 21, 2018

FACIT invests $450k in promising Ontario breakthrough technologies

FACIT Logo

Investment supports emerging entrepreneurial scientists and critical proof-of-principle studies

TORONTO, ON (February 20, 2018) – FACIT, a business accelerator, announced four new recipients of funding through its Prospects oncology investment competition: Dalriada Therapeutics Inc. (“Dalriada”), 16-Bit Inc. (“16-Bit”), a cancer biomarker study at the Ontario Institute for Cancer Research (“OICR”), and a virus-based therapeutic under development at the Ottawa Hospital and the University of Ottawa. FACIT’s investments are imperative in bridging the capital gap often experienced by early-stage Ontario companies, helping corporations establish jobs and build roots in the province. The wide ranging scope of the innovations, which span therapeutics, machine learning and biomarker development, reflect the rich talent pool within the Ontario oncology research community.

Continue reading – FACIT invests $450k in promising Ontario breakthrough technologies

January 25, 2018

The Canadian Data Integration Centre receives new funding to help cancer researchers translate findings to patients

CDI - LogoToronto (January 25, 2018) – The Canadian Data Integration Centre (CDIC) has received $6.4 million in funding from Genome Canada to help the research community translate the biological insights gained from genomics research into tangible improvements for cancer patients.

CDIC is a “one-stop shop” service delivery platform for cancer researchers, helping streamline research by providing coordinated expertise on a broad range of services, including data integration, genomics, pathology, biospecimen handling and advanced sequencing technologies. It is an international leader in genomics, bioinformatics and translational research, supporting some of the world’s largest programs in genomic data analysis, genomic and clinical data hosting, cancer data analyses and access, and the development of algorithms for advanced sequencing technology.

Continue reading – The Canadian Data Integration Centre receives new funding to help cancer researchers translate findings to patients

October 18, 2017

GA4GH Strikes Formal Collaborations with 15 International Genomic Data Initiatives

Orlando, Florida (October 17, 2017) – The Global Alliance for Genomics and Health (GA4GH) has struck formal collaborations with 15 international genomic data initiatives as 2017 Driver Projects, including Genomics England, Australian Genomics and the U.S. All of Us Research Program. The announcement, made at the GA4GH 5th Plenary Meeting, comes as part of the launch of GA4GH Connect: A 5-year Strategic Plan. GA4GH Connect aims to drive uptake of standards and frameworks for genomic data sharing within the research and healthcare communities in order to enable responsible sharing of clinical-grade genomic data by 2022.

Continue reading – GA4GH Strikes Formal Collaborations with 15 International Genomic Data Initiatives

October 4, 2017

FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A

Addition of new investors builds on Ontario’s next-gen radiotherapies and cancer innovations

Continue reading – FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A

August 15, 2017

New data resource centre will help better understand links between birth defects and childhood cancer

Researchers from the Ontario Institute for Cancer Research playing major role in the design and development of the new initiative.

Toronto (August 15, 2017) – Children with structural birth defects are at a much higher risk of developing certain types of childhood cancers but scientists currently lack vital information about why this occurs.

Continue reading – New data resource centre will help better understand links between birth defects and childhood cancer